Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts

US6900212B1 · kind B1 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Gerd Bartoszyk · Weiterstadt, DE
• Christoph Seyfried · Seeheim-Jugenheim, DE
• Christoph Von Amsterdam · Darmstadt, DE
• Henning Boettcher · Darmstadt, DE
• Ewen Sedman · Alresford, GB

Key dates

• Filing date: May 16, 2000
• Grant date: May 31, 2005
• Expiry date: May 16, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salts is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.